Fig. 1: Progression-free survival according to ribociclib relative DI in patients receiving ribociclib with first-line endocrine treatment (FAS; investigator assessment)a. | British Journal of Cancer

Fig. 1: Progression-free survival according to ribociclib relative DI in patients receiving ribociclib with first-line endocrine treatment (FAS; investigator assessment)a.

From: Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer

Fig. 1

DI dose intensity, FAS full analysis set. aPooled data: patients from MONALEESA-2 (ribociclib plus letrozole group), MONALEESA-3 (ribociclib plus fulvestrant group) and MONALEESA-7 (ribociclib plus non-steroidal aromatase inhibitor group).

Back to article page